• Develop the evidence your stakeholders require with industry experts

  • How can you satisfy the varying demands of regulators, payers, physicians and patients? Trust Quintiles to help optimize your real-world and late phase research.

    • Industry-leading experience – Specialized strategic, scientific, operational services and therapeutic and product lifecycle expertise
    • Full range of study types – From prospective observational research to interventional trials to EHR/retrospective database studies
    • Innovative technology – Designed specifically for the unique challenges of real-world and late phase studies
    • Real-world data analytics – Unique access to healthcare data through our exclusive databases and networks
  • Our Perspectives 

    slider image

    Outsourcing in a Changing Environment

    Head of US Commercial operations at Quintiles, Daryl Gaugler, presented ways to build strategic value by going beyond tactical commercial outsourcing. Review presentation

    slider image

    A Blueprint for Clinical / Commercial Convergence

    Bio pharmaceutical companies must shift from two divergent paths to one that combines clinical and commercial resources. Read white paper

  •  
     

    Video Spotlights 

  • Realize your product’s potential with post-marketing research

    Quintiles
    Before or after your product passes regulatory approval, real-world and late phase research can help you maximize your asset’s value.

    Interventional late phase trials require more agility when your market window is closing. Learn more

    Give payers evidence of real-world effectiveness to gain faster reimbursement. Find out how

    Now together for you – the leader in interventional late phase trials and the leader in observational research. Read more

  • Featured News

    Quintiles’ First Quarter 2014 Earnings Call Scheduled for Thursday, May 1st
    Read more

    Quintiles Appoints Dr. Stella Blackburn to Lead Global Risk Management
    Read more

    Quintiles Announces Exercise of the Underwriters’ Option to Purchase Additional Secondary Shares
    Read more

    Our Perspectives

    The Collaboration Mandate
    Read more

    Partnerships, Patients and Proof
    Read more

    Biomarkers: Recent Advances in their Application to the Treatment of Hematologic Malignancies
    Read more